Stephens & Co. Reiterates Overweight on Castle Biosciences, Maintains $37 Price Target
Portfolio Pulse from Benzinga Newsdesk
Stephens & Co. analyst Mason Carrico has reiterated an Overweight rating on Castle Biosciences (NASDAQ:CSTL) and maintained a $37 price target.
August 06, 2024 | 3:44 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Stephens & Co. analyst Mason Carrico has reiterated an Overweight rating on Castle Biosciences (NASDAQ:CSTL) and maintained a $37 price target.
The reiteration of an Overweight rating and the maintenance of a $37 price target by a reputable analyst can positively influence investor sentiment and potentially drive the stock price up in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100